Mantle Cell Lymphoma

Nilanjan Ghosh, MD, PhD, discusses the role of BTK inhibitors in B-cell malignancies and ongoing research with each agent.

Nilanjan Ghosh, MD, PhD, compares different BTK inhibitors in B-cell malignancies.

Nilanjan Ghosh, MD, PhD, discusses global trials examining zanubrutinib in mantle cell lymphoma and non-Hodgkin lymphoma.

Peter Martin, MD, provides an overview of what the current MCL treatment paradigm looks like as well as areas of future exploration and debate.

Matthew S. Davids, MD, MMSc, discusses ​remaining questions with umbralisib plus ibrutinib in chronic lymphocytic leukemia and mantle cell lymphoma.

Investigators from John Theurer Cancer Center participated in the pivotal ZUMA-2 clinical trial, which assessed the safety and effectiveness of brexucabtagene autoleucel in patients with relapsed or refractory mantle cell lymphoma.

Michael Wang, MD, discusses the safety profile of ​the CAR T-cell therapy brexucabtagene autoleucel in ​relapsed/refractory mantle cell lymphoma.

In our exclusive interview, Michael Wang, MD, discusses the FDA approval of brexucabtagene autoleucel in mantle cell lymphoma and ongoing research aimed at optimizing the safety and persistence of the product.

Michael Wang, MD, discusses the FDA approval of brexucabtagene autoleucel in mantle cell lymphoma and ongoing research aimed at optimizing the safety and persistence of the product.

Gaël Roué, PhD, discusses the rationale to evaluate the novel irreversible BTK inhibitor TG-1701 in preclinical models of ibrutinib-resistant mantle cell lymphoma.

Michael Wang, MD, a professor in the Department of Lymphoma and Myeloma at The University of Texas MD Anderson Cancer Center, discusses the FDA approval of brexucabtagene autoleucel (Tecartus; formerly KTE-X19) in mantle cell lymphoma (MCL).

The FDA has approved the CAR T-cell therapy brexucabtagene autoleucel (Tecartus; formerly KTE-X19) as a treatment for adult patients with relapsed/refractory mantle cell lymphoma.

Lori A. Leslie, MD, discusses current treatment options for patients with relapsed/refractory mantle cell lymphoma.

Lori A. Leslie, MD, discusses the current treatment landscape in mantle cell lymphoma, factors to consider when selecting between BTK inhibitors, and other treatment options on the horizon.

Matthew S. Davids, MD, MMSc, discusses the potential utility of moving the combination of ibrutinib and umbralisib into the frontline setting of chronic lymphocytic leukemia and mantle cell lymphoma.

Lori A. Leslie, MD, discusses the encouraging evolving treatment landscape in mantle cell lymphoma.

Lori A. Leslie, MD, discusses the role of BTK inhibitors in relapsed/refractory mantle cell lymphoma.

Gaël Roué, PhD, senior scientist at Josep Carreras Leukaemia Research Institute, discusses the next steps with the investigational BTK inhibitor TG-1701 in mantle cell lymphoma.

Matthew S. Davids, MD, MMSc, discusses the potential utility of ibrutinib in combination with umbralisib in patients with mantle cell lymphoma or relapsed/refractory chronic lymphocytic leukemia.

Lori A. Leslie, MD, discusses the current frontline treatment landscape in mantle cell lymphoma.

Peter Martin, MD, discusses the frontline treatment landscape of mantle cell lymphoma.

Lori Leslie, MD, discusses key questions to address with future research efforts in mantle cell lymphoma.

Gaël Roué, PhD, discusses interest regarding the novel irreversible inhibitor TG-1701 in models of ibrutinib (Imbruvica)-resistant mantle cell lymphoma.

Lori A. Leslie, MD, discusses the benefits with zanubrutinib (Brukinsa) in the treatment of patients with mantle cell lymphoma.

Matthew S. Davids, MD, MMSc, discusses updated findings from a phase 1/1b study which examined the combination of ibrutinib (Imbruvica) and umbralisib in relapsed/refractory chronic lymphocytic leukemia and mantle cell lymphoma.